Skip to main content

Stream every public session from the 27th annual Global Conference right here on our website.

Session Listing

Dates
Select All | None
Tuesday, December 6, 2022
Wednesday, December 7, 2022
Thursday, December 8, 2022
Tracks
Click All | None
AI, Innovation, & Technology
Business & Industry
Diversity, Equity, & Inclusion
Financial Markets
Health & Medical Research
Human Capital, Jobs, & Education
Philanthropy & Social Impact
Policy, Politics, & Regulation
Society & Culture
Sustainability & Environment

Badge Pick-up
07:00 AM - 07:30 PM
Salamander Washington DC - Grand Foyer
Partnering for Patients Forum Networking Breakfast
07:30 AM - 08:30 AM
Salamander Washington DC - Marina I and II
Time=Lives and Value-based Payment Models: Are They Working?
08:30 AM - 10:00 AM
Salamander Washington DC - Gallery C

This session will open with a Time=Lives Talk by Sandra Abrevaya and Brian Wallach, Co-Founders of I AM ALS, followed by a panel discussion on Value-based Payment Models.

Value-based payment has long been viewed as a key approach to facilitating access while ensuring accountability for costs and quality. But when it comes to transformative technologies, such as gene therapies that carry price tags much higher than conventional therapies, are value-based payment models still the right approach? In this session, experts will discuss successes and challenges of implementing value-based payment. They will further explore how models are evolving to accommodate gene therapies. 

Guests
Sandra Abrevaya
Co-Founder and CEO, Synapticure; Co-Founder, I AM ALS
Brian Wallach
Co-Founder and Board Chair, Synapticure; Co-Founder, I AM ALS
Moderator
Aneesh Chopra
President, CareJourney
Speakers
Lee Fleisher
Chief Medical Officer and Director, Center for Clinical Standards and Quality, Centers for Medicare & Medicaid Services
Maia Z. Laing
Patient Advocate, Zakara Inc.
Hoangmai Pham
Founder and President, Institute for Exceptional Care
Jack Rollins
Director of Federal Policy, National Association of Medicaid Directors
Business & Industry Health & Medical Research

This session will open with a Time=Lives Talk by Sandra Abrevaya and Brian Wallach, Co-Founders of I AM ALS, followed by a panel discussion on Policymaking as a Driver of Progress.

Recent efforts to engage US patients in biomedical research have been bolstered by policymakers and congressional action. The 21st Century Cures Act (Cures 1.0), 2016, strengthened the accrual and use of patient experience data as part of the research and regulatory review process. Additional efforts through the FDA Reauthorization Act, 2017, and the Prescription Drug User Fee Act, starting with the fifth reauthorization, included provisions to expand patient-focused drug development and patient engagement. International regulatory and policy-making bodies increasingly emphasize expanding patient engagement and using patient perspectives and data to inform their decisions. Considering legislation currently in progress, this session will examine what stakeholders can expect from the move toward greater representation of patients' voices and perspectives in the product-development cycle. Panelists will explore how existing and pending legislation could fill key gaps and drive progress.

Guests
Sandra Abrevaya
Co-Founder and CEO, Synapticure; Co-Founder, I AM ALS
Brian Wallach
Co-Founder and Board Chair, Synapticure; Co-Founder, I AM ALS
Moderator
Steve Usdin
Senior Editor, Washington, BioCentury
Speakers
Rachele Berria
Vice President, Head of Medical US BioPharmaceuticals, AstraZeneca
Michael Boyle
Senior Vice President and Chief Policy and Advocacy Officer, Cystic Fibrosis Foundation
Theresa Mullin
Associate Director for Strategic Initiatives, Center for Drug Evaluation and Research, US Food and Drug Administration
Yvette Venable
Vice President of Patient Engagement, Institute for Clinical and Economic Review
Policy, Politics, & Regulation

The Food and Drug Administration's (FDA) expedited review processes have been instrumental in making treatments available for individuals living with serious illnesses. Manufacturers of new medical products leverage the four expedited programs: (1) priority review; (2) accelerated approval; (3) fast-track, and (4) breakthrough therapy to accelerate drug development and review. While these programs have been undoubtedly successful in fulfilling the goals for which they were introduced, they also attract their fair share of scrutiny, especially the accelerated approval pathway. Over the years, several drugs approved under the accelerated approval pathway have proven controversial and called into question concerns about patient safety for failure of sponsors to complete post-approval confirmatory studies. A recent FDA drug approval decision thrust the approval pathway into the spotlight. This session will review the successes of the accelerated approval pathway for the patient community, reform efforts underway, and how stakeholders are balancing the utility of expedited approval programs with concerns raised about their effectiveness. 

Moderator
Michael McCaughan
Founder, Prevision Policy
Speakers
Jeff Allen
President and CEO, Friends of Cancer Research
Holly Fernandez Lynch
Assistant Professor of Medical Ethics and Law, University of Pennsylvania
Frank Sasinowski
Director, Hyman, Phelps & McNamara
Jamie Sullivan
Senior Director of Policy, EveryLife Foundation for Rare Diseases
Health & Medical Research Policy, Politics, & Regulation
Foundations as Trusted Intermediaries for Patient Data Resources
10:30 AM - 11:30 AM
Salamander Washington DC - Gallery A

Analyzing data from and about patients is essential to advance biomedical research, but its collection and dissemination require significant investment of time and resources for patient organizations that choose to be the intermediary. Patient groups and their research collaborators must determine what data is needed and how to collect and manage it ethically and securely. They must also determine what can be shared and how to fund their efforts long term. In this session we'll hear from emerging nonprofit innovators about the opportunities and challenges they see as they position themselves as honest brokers for this most precious of research resourcesour personal health data. 

Moderator
Jen Horonjeff
Founder and CEO, Savvy Cooperative
Speakers
Beth Dean
CEO, CURE Epilepsy
Kirk Nylen
Deputy Scientific Director, Ontario Brain Institute
Kapila Viges
CEO, MPN Research Foundation
Kate Wears
Executive Director, Myhre Syndrome Foundation
Health & Medical Research
Creating New Markets for Approved Drugs (Invite only)
10:30 AM - 11:30 AM
Salamander Washington DC - Phillips

Across a wide range of diseases, repurposing drugs already approved for other indications is a popular strategy, as evidence already exists about their safety and other properties. Significant business model challenges have prevented their widespread development and use, however, how can we better attract private capital to accelerate these ideas through the commercialization process? What types of compounds are most amenable to policy efforts that might help change this landscape?

Moderator
Mike Rea
CEO, IDEA Pharma
Speakers
Howard Fillit
Co-Founder and Chief Science Officer, Alzheimer's Drug Discovery Foundation
Sandi Heibel
Chief Operating Officer, Audacity Therapeutics
Ethan Perlstein
CEO, Perlara
Heather Stone
Health Science Policy Analyst, US Food and Drug Administration
Health & Medical Research

Consideration of patients' needs, experiences, and perspectives can contribute to medical product development processes, as well as inform regulatory and access decision-making. Patient perspectives and data are useful in validating and qualifying product development tools and resources, modifying product labeling, and aiding patient access to novel therapies. However, the need remains for greater guidance and stricter standards on how to share and apply patient information uniformly and consistently. Speakers intend to share a few case studies highlighting how patient-focused product development has contributed to and informed regulatory decision-making. They will examine opportunities for better integration of the patient's voice in product development and regulatory decisions, and how to align stakeholders in collaborating with the patient community to address unmet medical needs.

Moderator
Cartier Esham
Chief Scientific Officer and EVP of Emerging Companies, Biotechnology Innovation Organization (BIO)
Speakers
Robyn Bent
Director, CDER Patient Focused Drug Development Program, US Food and Drug Administration
Mary Elmer
Executive Director Patient Engagement Oncology, Merck
Sonya Eremenco
Executive Director, Patient-Reported Outcome Consortium, Critical Path Institute
Andrew Fish
President and CEO, Medical Device Innovation Consortium
Ceciel Rooker
President and Executive Director, International Foundation for Gastrointestinal Disorders
Health & Medical Research
Why Is It Still So Hard for People to Get Their Health Data?
12:00 PM - 01:30 PM
Salamander Washington DC - Gallery A

Patients are the source, active or passive, of most of the data driving discovery and innovation in biomedical R&D and improvements in care. Many of us have relatively easy and centralized access to our financial data, but few of us can say the same about our health data. Countless efforts have been made to address this issue, including the very recent federal Cures Act Final Rule, which requires that patients be able to electronically access all their records at no cost. What is still standing in our way? Only when patients have easier access to their data, more control over its use, and trust in the intermediaries can true transformation occur in the health data ecosystem. 

Moderator
Deven McGraw
Lead, Data Stewardship and Data Sharing, Invitae
Speakers
Elise Berliner
Global Senior Principal of Real World Evidence Strategy, Cerner Enviza
Harlan Krumholz
Co-Founder, Hugo Health; Harold H. Hines, Jr. Professor of Medicine and Director, Center for Outcomes Research and Evaluation, Yale University School of Medicine
Peter Levin
Co-Founder and CEO, Amida
Anna McCollister
Independent Consultant, Patient Engagement and Data Use, Access and Governance
Steve Posnack
Deputy National Coordinator for Health Information Technology, US Department of Health and Human Services
Health & Medical Research
Improving Health Equity in Rare Diseases Research
02:00 PM - 03:00 PM
Salamander Washington DC - Gallery C

People with rare diseases face many barriers and inequities in accessing diagnosis, treatment, and comprehensive care. This burden is even greater among marginalized communities with rare diseases. The disparities fall into three major categories: lack of diversity in preclinical and clinical data; lack of diversity in the membership in and leadership of patient advocacy organizations; and limited health care and research access, from diagnosis to insurance coverage, to representation in rare disease clinical trials. The result is underrepresentation of marginalized groups and research that does not accurately reflect the comprehensive needs and experiences of the impacted population. This session will highlight these challenges, discuss solutions already being implemented, and imagine what true health equity for people with rare diseases would be. 

Moderator
Nicholas St. Fleur
Science Reporter and Associate Editorial Director of Events, STAT; Host of "Color Code" Podcast
Speakers
Nicole Boice
Executive Director, Rare-X
Donna Cryer
President and CEO, Global Liver Institute
Mary McGowan
CEO, Foundation for Sarcoidosis Research
Tamar Thompson
Head of Global Corporate Affairs, Alexion, AstraZeneca Rare Disease
Health & Medical Research Diversity, Equity, & Inclusion
Innovation in Biomarker Development and Deployment
02:00 PM - 03:00 PM
Salamander Washington DC - Gallery A

Validated biomarkers are an essential and often under-appreciated tool for detecting and treating diseases, improving drug development, and informing regulatory decision making. Recent advances in genetic and molecular technologies are leading to the identification of sensitive, specific, and validated biomarkers for numerous diseases, including multiple sclerosis, pancreatic cancer, Alzheimer's disease, and more. Development of biomarkers that rely on digital technologies are of great interest to many stakeholders. What is new and promising in this realm of critical tools for the biomedical innovation ecosystem? Are issues of access to these tools by physicians and patients being addressed?

Moderator
Charles Ryan
President and CEO, Prostate Cancer Foundation
Speakers
Mark Allegretta
Vice President, Research, National MS Society
Namandje Bumpus
Chief Scientist, US Food and Drug Administration
Julie Louise Gerberding
CEO, Foundation for the National Institutes of Health
Varun Renjen
Managing Director-Health Care and Life Sciences Deal Advisory and Strategy, KPMG
Health & Medical Research

Industry and patient organizations can work together to streamline the process of acquiring and incorporating patient input in biomedical research. Patient organizations already drawing on limited resources to fulfill a variety of functions in research, education, and advocacy are further burdened by multiple, duplicative demands for patient data. Product sponsors are increasing the ways they engage patients in R&D processes, putting additional demands on patient organizations and communities. Product sponsors have an opportunity to partner with patient organizations in a systematic, efficient way, enabling the patient community to anticipate sponsors' needs for patient input early in the research process. Patient partners can thus help build capacity and the requisite knowledge base to address sponsors' demands, and shape partnerships to identify the right patient input for biomedical research. In this session patient organizations, product sponsors, and other key R&D stakeholders will meet to discuss the challenges stakeholder groups confront in research-partnership coordination. They will explore solutions to improve and streamline partnerships for patient engagement in future research collaborations.  

Moderator
Susan Winckler
CEO, Reagan-Udall Foundation for the Food and Drug Administration
Speakers
Annette Bakker
President, Children's Tumor Foundation
Marc Hurlbert
CEO, Melanoma Research Alliance
Christa Kerkorian
Vice President, Patient Advocacy, Day One Bio
Amy Miller
President, PhRMA Foundation
Health & Medical Research
Time=Lives and Building the Clinical Trial Enterprise of the Future
03:30 PM - 04:45 PM
Salamander Washington DC - Gallery C

This session will open with a Time=Lives Talk by Casey McPherson, Co-Founder and Chief Innovation Officer, Everlum Bio and Founder and President, To Cure A Rose Foundation, followed by a panel discussion on Building the Clinical Trial Enterprise of the Future.

Clinical trials are a lengthy and expensive phase in the development of new products to treat and prevent disease. While much has been written about the need to streamline the clinical development process, there has been little substantive change. Three areas need urgent attention: The clinical trial enterprise of the future should more closely reflect the social burden of disease, particularly on underrepresented groups; it should more fully embrace the opportunities of digital disruption; and it should eliminate steps that cost money and time without adding value. What can be done to bring about these and other efficiencies? What other changes to clinical trial phase of drug development will be necessary to create a patient-centered health delivery system in the foreseeable future?

Guest
Casey McPherson
Co-Founder and Chief Innovation Officer, Everlum Bio; Founder and President, To Cure A Rose Foundation
Moderator
Adrian Hernandez
Executive Director, Duke Clinical Research Institute
Speakers
Louis DeGennaro
President and CEO, Leukemia & Lymphoma Society
Eric Lefkofsky
Founder and CEO, Tempus
William Pao
Chief Development Officer and Executive Vice President, Pfizer
Janet Woodcock
Principal Deputy Commissioner, US Food and Drug Administration
Health & Medical Research Policy, Politics, & Regulation
Time=Lives and Overcoming Challenges to Drug Repurposing
03:30 PM - 04:45 PM
Salamander Washington DC - Gallery A

New drugs can take more than a decade to develop and get to market. Drug repurposingwhich involves taking an existing drug or drug candidate and using it for a disease that is different from what it was originally developed to treatcan potentially lower costs and shorten development timelines. But does it work? And if so, what barriers continue to stand in the way of it becoming a more widely accepted path, especially for drugs that are already approved? In this session, we will discuss the progress and challenges for drug repurposing as well as lessons learned in the search for COVID-19 therapies.

This session will close with a Time=Lives Talk by Casey McPherson, Co-Founder and Chief Innovation Officer, Everlum Bio and Founder and President, To Cure A Rose Foundation.

Guest
Casey McPherson
Co-Founder and Chief Innovation Officer, Everlum Bio; Founder and President, To Cure A Rose Foundation
Moderator
Tanisha Carino
Partner, Brunswick Group
Speakers
David Fajgenbaum
Co-Founder and Executive Director, Castleman Disease Collaborative Network
Mike Rea
CEO, IDEA Pharma
Joni Rutter
Director, National Center for Accelerating Translational Science, National Institutes of Health
Peter Stein
Director, Office of New Drugs, US Food and Drug Administration
Health & Medical Research

Over half (six in ten) Americans live with a chronic disease, and four in ten live with at least two. Obesity, diabetes, hypertension, and hypercholesterolemia are common in US. Not only are these conditions associated with increased risk of poor outcomes with COVID-19 infection, they alsoalone or in combinationcan result in devasting complications as they progress. These include chronic kidney disease and dementia, leading to lower quality of life, and driving the 4.1 trillion annual health-care costs. To tackle these complex health issues, a collection of diverse stakeholders, in conjunction with a whole-of-society approach are needed to create a vision of change, assume leadership, identify supporting roles, and outline the partnerships and collaborations needed to move forward with intention and urgency. This private session brings together a diverse group of participantsincluding policymakers, non-profit and private sector leaders, as well as nontraditional health sector representativesfor an informative, candid discussion about the policy priorities and investments needed to collectively address the burgeoning chronic disease challenges.

Moderator
Sarah Wells Kocsis
Director, Center for Public Health, Milken Institute
Speakers
Shereef Elnahal
Under Secretary for Health, United States Department of Veterans Affairs, US Department of Veterans Affairs
Lynn Goldman
Michael and Lori Milken Dean of Public Health, George Washington University
Dean Ornish
Founder and President, Preventive Medicine Research Institute
George Vradenburg
Chairman, UsAgainstAlzheimer's
Melicia Whitt-Glover
Executive Director, Council on Black Health; President and CEO, Gramercy Research Group
Policy, Politics, & Regulation
Long COVID: A Conversation with US Senator Tim Kaine
05:00 PM - 05:20 PM
Salamander Washington DC - Grand Ballroom
Guest
Tim Kaine
US Senator, Virginia
Moderator
Eugene Daniels
Playbook Author and White House Correspondent, Politico
Future of Health Summit Reception
05:30 PM - 06:30 PM
Salamander Washington DC - Grand Foyer
Global Health Reception (Invite only)
05:30 PM - 06:30 PM
Salamander Washington DC - Marina II

The COVID-19 pandemic has transformed how we think about the world's health, economies, and societies. It has also served as a powerful reminder of the need for collaboration and partnership. This private reception will provide an opportunity to engage with other leaders in global health and to learn about ways to participate in the Milken Institute's ongoing work in the area.

Opening Remarks
Esther Krofah
Executive Vice President, MI Health, Milken Institute
Speakers
Priya Basu
Executive Head, The Pandemic Fund Secretariat, World Bank Group
Raj Panjabi
Special Assistant to the President and Senior Director for Global Health Security and Biodefense, National Security Council, The White House

The new year will begin with fresh leadership at several of the nation's top scientific agencies. Hear from Dr. Bertagnolli and Dr. Wegrzyn about where they see the greatest opportunities to improve health and what changes to the biomedical innovation ecosystem are needed to realize that promise. 

Opening Remarks
Mr. Michael Klowden
CEO, Milken Institute
Guest
Michael Milken
Chairman, Milken Institute
Moderator
Francis Collins
16th Director, National Institutes of Health
Speakers
Monica Bertagnolli
Director, National Cancer Institute
Renee Wegrzyn
Inaugural Director, Advanced Research Projects Agency for Health (ARPA-H)
Health & Medical Research

Badge Pick-up
07:30 AM - 06:00 PM
Salamander Washington DC - Grand Foyer
Future of Health Summit Opening Plenary
08:30 AM - 10:00 AM
Salamander Washington DC - Grand Ballroom
Part 1: A Conversation with FDA Commissioner Robert Califf
08:30 AM - 09:00 AM
Salamander Washington DC - Grand Ballroom
Welcome Remarks
Esther Krofah
Executive Vice President, MI Health, Milken Institute
Guest
Rob Califf
Commissioner, US Food and Drug Administration
Moderator
Michael Milken
Chairman, Milken Institute
Policy, Politics, & Regulation
Part 2: Defining Moments in Health: Leading Through Turbulent Times
09:00 AM - 10:00 AM
Salamander Washington DC - Grand Ballroom

The past two years have been marked by moments that define a generationthe COVID-19 pandemic, supply chain breakdowns, a shift in American political power, unprecedented social movements, and more have all fundamentally changed how leaders lead. As the next decade unfurls and we look ahead to the uncertainty it may bring, how can C-suite members provide steadying and calm guidance for their companies? This panel featuring leaders from the health-care sector will seek answers to the question: How do you lead through the unknown? 

Moderator
Bertha Coombs
Reporter, CNBC
Speakers
Bruce Broussard
President and CEO, Humana
Lawrence Tabak
Senior Official Performing the Duties of the NIH Director, National Institutes of Health
John Wigneswaran
Chief Medical Officer, Walmart
Angela Williams
President and CEO, United Way Worldwide
George Yancopoulos
Co-Founder, President, and Chief Scientific Officer, Regeneron Pharmaceuticals
Business & Industry
Center for the Future of Aging Advisory Board Breakfast (Invite only)
08:30 AM - 10:00 AM
Salamander Washington DC - Marina II

The Milken Institute Center for the Future of Aging Advisory Board is comprised of the Leadership Council and the Academic and Policy Council, influential leaders and experts working to ensure that individuals, institutions, and societies are prepared for an aging population. The Center's Future of Health Advisory Board meeting will feature opening remarks and a fireside conversation with US Representative Debbie Dingell, updates on Center initiatives, and a fireside conversation with Bill Novelli, founder of Georgetown Business for Impact and former CEO of AARP. The discussion will elevate new ideas and multi-sectoral opportunities to build an age-integrated society. 

Speakers
Debbie Dingell
US Representative, Michigan
Bill Novelli
Professor Emeritus, McDonough School of Business, Georgetown University
FasterCures Advisors Meeting: A Conversation with Meena Seshamani (Invite only)
10:15 AM - 11:30 AM
Salamander Washington DC - Phillips

This annual meeting brings together the FasterCures Advisory Groups, including the Board, Business Council, and Changemakers nonprofit advisory council, to discuss timely topics across the biomedical research ecosystem. Dr. Meena Seshamani, the Deputy Administrator and Director of Center for Medicare at CMS will be the featured guest. Advisory group members will have the opportunity to provide their perspectives on the implementation of the Medicare-related provisions in the Inflation Reduction Act of 2022.

Opening Remarks
Esther Krofah
Executive Vice President, MI Health, Milken Institute
Guest
Meena Seshamani
Deputy Administrator and Director of Center for Medicare, Centers for Medicare & Medicaid Services
Moderator
Kristin Schneeman
Senior Director, FasterCures, Milken Institute

This session will open with a conversation with Representative Anna Eshoo, followed by a panel discussion on ARPA-H.

The signature achievements of the federal Defense Advanced Research Projects Agency (DARPA) are well known. Among them were early iterations of the internet, wireless communication, speech recognition, and global positioning systems. More than a decade of advocacy for a similar agency targeting high-risk, high-reward innovations in health has borne fruit in the creation of the Advanced Research Projects Agency for Health (ARPA-H) in 2022. What problems should this new entity focus on solving? How should ARPA-H be structured if it is to achieve the same quality of breakthroughs as DARPA? 

Guest
Anna Eshoo
US Representative, California; Chair, US House Energy and Commerce Subcommittee on Health
Moderators
Margaret Anderson
Managing Director, Deloitte
Esther Krofah
Executive Vice President, MI Health, Milken Institute
Speakers
Christopher Austin
CEO and Partner, Flagship Pioneering
Howard Fillit
Co-Founder and Chief Science Officer, Alzheimer's Drug Discovery Foundation
Susan Monarez
Acting Deputy Director, Advanced Research Projects Agency for Health (ARPA-H)
Tara Schwetz
Acting Principal Deputy Director, National Institutes of Health
Michael Stebbins
President, Science Advisors
Health & Medical Research
Reimagining the Pharmaceutical Supply Chain in the United States
10:30 AM - 11:30 AM
Salamander Washington DC - Gallery A

Ideally, our nation's pharmaceutical supply chain should provide medicines and medical supplies of the highest quality, in the right quantity, to the right customer at the right place. Supplies should arrive at the right time, and at a fair cost that is aligned with broader public health improvement goals for individuals and communities. Panelists will explore the dynamics of the pharmaceutical supply chain in the US from the public health perspective, drawing on lessons learned from the COVID-19 pandemic. Subject matter experts will discuss upstream and downstream aspects of today's supply chain, and envision the future of the pharmaceutical supply chain to realize optimal efficiency, delivery, and resilience across the US health-care ecosystem while advancing public health. 

Moderator
Sarah Owermohle
Washington Correspondent, STAT
Speakers
Tom Cotter
Executive Director, Healthcare Ready
Chip Davis
President and CEO, Healthcare Distribution Alliance
Mark McClellan
Director, Duke-Margolis Center for Health Policy, Duke University
Gary Puckrein
President and CEO, National Minority Quality Forum
Business & Industry

Trust is a responsibility and a fragile commodity that rests on societal pillars. Trust from employees can catalyze societal change. Employers can advocate for communities through their speech and actionsor by silence and inaction. Employers can rise to the moment by proactively keeping a monitoring finger on the pulse of the total health impact employees confront daily, from local concerns and world issues to public health priorities. Systemic racism, war, gun violence, death by suicide, overdoses, drug poisoning, economic uncertainty, COVID-19: These threats impact us all, whether directly or indirectly. To achieve the goal of widespread, whole-person health, employers must aim for transparency, set measurable goals to hold themselves accountable, continue to listen, and anticipate their employees' needs. It's critical to invest in resources and tools that are easy to navigate, customize, and adapt to the needs of a diverse and evolving workforce.

Moderator
Tina Reed
Health Care Editor, Axios
Speakers
Kiran Ahuja
Director, United States Office of Personnel Management
Shari Conaway
Senior Director, People, Southwest Airlines
Roger Krone
CEO, Leidos
DeAnna Minus-Vincent
Executive Vice President and Chief Social Justice and Accountability Officer, RWJ Barnabas Health
Business & Industry Human Capital, Jobs, & Education
Cell and Gene Therapies: Are We Setting the Right Expectations? (Invite only)
12:00 PM - 01:30 PM
Salamander Washington DC - Phillips

Cell and gene therapies are generating excitement for their potential to treat diseases more precisely, but are expectations for these therapies realistic? Today, efforts are underway by multiple entities to create patient and provider educational resources that aim to illuminate how these therapies work. Are these materials answering the right questions? How well do our heterogeneous patient communities understand the common misconceptions about cell and gene therapies? Are we taking the right steps to ensure that the hopes for cell and gene therapies remain consistent with reality? 

Moderator
Sung Hee Choe
Senior Director, FasterCures, Milken Institute
Speakers
Juliet K. Choi
President and CEO, Asian and Pacific Islander American Health Forum
Mark Skinner
President and CEO, Institute for Policy Advancement
Kevin Wake
President, Uriel Owens Sickle Cell Disease Association of the Midwest
Health & Medical Research
Center for Public Health Advisory Board Meeting (Invite only)
12:00 PM - 01:30 PM
Salamander Washington DC - Marina I
Lunch Plenary
12:00 PM - 01:45 PM
Salamander Washington DC - Grand Ballroom
Part 1: A Conversation with US Senator Bill Cassidy
12:00 PM - 12:45 PM
Salamander Washington DC - Grand Ballroom
Opening Remarks
Melissa Stevens
Executive Vice President, MI Philanthropy, Milken Institute
Guest
Bill Cassidy
US Senator, Louisiana
Moderator
Michael Milken
Chairman, Milken Institute
Part 2: The Future of the mRNA Revolution
12:45 PM - 01:45 PM
Salamander Washington DC - Grand Ballroom

Messenger RNA, or mRNA, has been a focus of research for scientists and drug developers for many years. It jumped to the forefront of the public consciousness when rapidly and successfully deployed as the platform for COVID-19 vaccines. The technology, however, promises to address a wider range of conditions, from cancers to cardiovascular disease to a broad array of infectious diseases. Learn more about the inner workings of mRNA and its promise as a treatment modality. 

Moderator
Matt Herper
Senior Writer, Medicine, Editorial Director of Events, STAT
Speakers
Vinod Balachandran
Member Researcher and Surgical Oncologist, David M. Rubenstein Center for Pancreatic Cancer Research
Thomas Conlon
Chief Scientific Officer, Michelson Philanthropies and the Michelson Found Animals Foundation
Mark Feinberg
President and CEO, International AIDS Vaccine Initiative (IAVI)
Ansbert Gadicke
Managing Partner, BioImpact Capital and Managing Director, MPM Capital
Mary Marovich
Director, Vaccine Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Health & Medical Research
Building Resilient Food Systems: Applying Lessons from Disaster Response
02:00 PM - 03:00 PM
Salamander Washington DC - Gallery B

With food system and supply chain shocks increasing in frequency and severity due to climate change, public health emergencies, and conflict, the need for a resilient multi-level food system has become ever more apparent. Over the course of the pandemic, the public, private, and nonprofit sectors of food supply and distribution have responded with unprecedented speed and creativity to the challenges created by the lockdown and its aftermath. In this session, food system stakeholders from academia, industry, and policy will discuss the lessons and strategies for responding to disasters while simultaneously building a more nutritious, equitable, and sustainable food system that is equipped for the future.

Moderator
Holly Freishtat
Director, Feeding Change, Milken Institute
Speakers
Claire Babineaux-Fontenot
CEO, Feeding America
Martin Bloem
Professor of Environmental Health, The Johns Hopkins Bloomberg School of Public Health
Nancy Dalton
Head of Marketing and Community Partnerships, Amazon
Tatiana Granados
Co-Founder and Chief Operating Officer, Common Market
Sustainability & Environment
Charting a New Course: Investing in Women's Health
02:00 PM - 03:00 PM
Salamander Washington DC - Gallery C

More than half of the total population are women, but under-investment in women's health remains a chronic problem. Despite being the primary health-care decision makers, women's perspectives, health needs, and capabilities are frequently ignored, resulting in disparities in health outcomes. Recent research suggests that even modest increases in funding for women's health research have the potential to yield very large gains, including reduced health-care costs, increased labor productivity, and improved quality of life for women. This session will explore the dynamic state of women's health and examine ways in which better targeted investment, research, technology, and innovation in the field of women's health can reap benefits for us all. 

Moderator
Alice Miranda Ollstein
Health Care Reporter, Politico
Speakers
Janine Austin Clayton
Director, Office of Research on Women's Health, National Institutes of Health
Linda Blount
President and CEO, Black Women's Health Imperative
Elizabeth Galbut
Co-Founder and Managing Partner, SoGal Ventures
Julie Khani
Vice President, Government Affairs, Hologic
Health & Medical Research Diversity, Equity, & Inclusion
Is AI Just What the Doctor-or Patient-Ordered?
02:00 PM - 03:00 PM
Salamander Washington DC - Gallery A

Machine learning and artificial intelligence, along with the algorithms that underpin them, hold great promise to improve health-care decision-making and biomedical innovation. But, as these powerful tools become an integral part of our lives, they pose unique challenges in areas of personal health-care information storage and use. What kinds of solutions could these technologies enable? What do patients and the general public need to understandand consent toabout how their data is being used? What are the potential ethical and security downsides and pitfalls? 

Moderator
Ruth Reader
Health and Technology Reporter, Politico
Speakers
Blythe Adamson
Principal Scientist, Machine Learning, Flatiron Health
Joe Franklin
Head of Strategic Affairs, Clinical Studies Platforms, Verily Life Sciences
John Halamka
President, Mayo Clinic Platform
Colin Hill
CEO and Co-Founder, GNS Healthcare
Cynthia Rice
Chief Mission Strategy Officer, JDRF
AI, Innovation, & Technology

To promote health equity within the biomedical research and health-care systems, we must focus on having a culturally competent and diverse workforce. Greater diversity at all levels of health-care delivery and research will be critical to building trust and participation within patient communities where the need is greatest. Greater diversity will also ensure that more research is carried out on the health-care needs of underserved populations. Addressing the lack of a diverse workforce requires developing diverse leadership across all sectors touching on health care and medicine. In this session, panelists will (1) explore the role of biopharma, academia, health-care providers, and policymakers in eliminating systemic inequities and biases that exacerbate mistrust; (2) consider how fellowships and training programs are responding to the need for greater diversity in medicine and health care; and (3) discuss novel funding, training, and engagement solutions for building a culturally competent, diverse health-care workforce.

Moderator
Yasmeen Long
Director, FasterCures, Milken Institute
Speakers
Blayne Cutler
President and CEO, Heluna Health
Maurice Jones
CEO, One Ten
Kameron Matthews
Chief Health Officer, Cityblock Health
Health & Medical Research Diversity, Equity, & Inclusion Human Capital, Jobs, & Education
Letting Smiles Shine: Oral Health as the Gateway to Health Equity
03:30 PM - 04:30 PM
Salamander Washington DC - Gallery B

While COVID masks have hidden smiles over the past few years, teeth continue to tell a compelling story of overall health and wellbeing. Although largely preventable, cavities are one of the most common chronic diseasesa quarter of young children, half of adolescents, and more than 90 percent of adults experience some form of tooth decay. Though often overlooked, regular dental care is associated with improved overall physical and mental healthtreating oral health complications can help prevent heart disease and dementia; periodontal disease, which affects nearly a quarter of those with diabetes, may cause blood sugar to rise, making treatment of diabetes more difficult. As with other social determinants of chronic diseases, there are stark disparities in oral health among racial, socioeconomic, gender, and geographic groups. Panelists will discuss innovative ways to improve the state of oral health in America and how doing so advances health equity. 

Moderator
Nicholas St. Fleur
Science Reporter and Associate Editorial Director of Events, STAT; Host of "Color Code" Podcast
Speakers
Gillian Barclay
Vice President, Global Public Health and Head of Bright Smiles, Bright Futures Program, Colgate-Palmolive
Arturo Brito
President and CEO, Children’s Health Fund
Natalia Chalmers
Chief Dental Officer, Centers for Medicare & Medicaid Services, US Department of Health and Human Services
Wells Hutchison
President and CEO, Delta Dental Plans Association
Health & Medical Research Policy, Politics, & Regulation
Tackling Chronic Disease: Creating Value and Impact through Upstream Intervention
03:30 PM - 04:30 PM
Salamander Washington DC - Gallery A

Life expectancy in the US fell by 2.26 years from 2019 to 2022, the biggest drop since WW II. COVID-19 accounts for 74 percent of the drop, but chronic conditionse.g., diabetes, heart disease, kidney diseasehave heavy health and economic costs. Of $4.1 trillion in US annual health expenditures, 90 percent goes to chronic conditions, including mental health. The numbers of US adults with diabetes and obesity are at epidemic levels. These conditions, along with COVID-19, are significantly increasing the prevalence of kidney disease. Population aging and lifestyle changes add to the increase, straining the health-care system. Trends are emerging toward upstream interventions using strategies to detect chronic diseases earlier and slow progression. Speakers will review trial approaches to improve population health and meet growing demands, e.g., for person-centered care and value-based payment models. They will discuss potential drivers of transformative change to modernize care, and clarify opportunities for reshaping chronic disease management. 

Moderator
Nicholas Florko
Washington Correspondent, STAT
Speakers
Derek Asay
Senior Vice-President, Lilly Value and Access, Eli Lilly and Company
Arta Bakshandeh
Chief Medical Informatics Officer, Alignment Health
Matt Eyles
CEO, America's Health Insurance Plans
Donna Grande
CEO, American College of Preventive Medicine
Dora Hughes
Chief Medical Officer, CMS Innovation Center, Centers for Medicare & Medicaid Services
Business & Industry Health & Medical Research

Philanthropy can drastically accelerate biomedical research. However, philanthropic dollars may do more harm than good, especially if funders fail to be mindful of sustainability, consider the current scale of available funding, or address specific barriers in the field. Under-resourced fields require significant coordination and partnerships to build an intentional funding strategy, infrastructure, and human capital necessary to grow the field and make discoveries. Philanthropic capital has the flexibility and tenacity to uncover and address the specific needs of research communities and the patience to deploy resources sustainably over time. Building trust, fostering community, and grasping the structural and scientific nuances in underfunded fields can both facilitate a monumental shift in the short-term while laying the groundwork for a lasting and outsized impact. 

Moderator
Melissa Stevens
Executive Vice President, MI Philanthropy, Milken Institute
Speakers
Cara Altimus
Senior Director, Center for Strategic Philanthropy, Milken Institute
Daniel Doctoroff
Chairman and Founder, Target ALS
Marilyn Simons
Co-Founder, Simons Foundation
Health & Medical Research Philanthropy & Social Impact
FasterCures Board Meeting (Invite only)
03:30 PM - 05:00 PM
Salamander Washington DC - Corcoran
A Conversation with CDC Director Rochelle Walensky
04:45 PM - 05:10 PM
Salamander Washington DC - Grand Ballroom
Guest
Rochelle Walensky
Director, Centers for Disease Control and Prevention; Administrator, Agency for Toxic Substances and Disease Registry
Moderator
Bertha Coombs
Reporter, CNBC
Health & Medical Research
A Revolution in Longevity Science
04:45 PM - 05:45 PM
Salamander Washington DC - Gallery B

People are living longer than ever before. On average, across OECD countries, at age 65, people can expect to live another 19.7 years. By the year 2050, there will be eight times as many centenarians as there are today. By studying the biology and psychology of aging, researchers are finding pathways that may allow us to stave off age-related diseases, such as dementia, and increase our lifespans and health spans. This session will explore new evidence regarding the best ways to extend healthy longevity and possibly reverse the aging process.  

Moderator
Anne Thompson
Chief Environmental Affairs Correspondent, NBC News
Speakers
Nir Barzilai
Director, Institute for Aging Research
Roberta Brinton
Director and Regents Professor, Center for Innovation in Brain Science at the University of Arizona
Martin Dewhurst
Global Co-Leader, McKinsey Health Institute
Howard Fillit
Co-Founder and Chief Science Officer, Alzheimer's Drug Discovery Foundation
Dean Ornish
Founder and President, Preventive Medicine Research Institute
Health & Medical Research
Harnessing the Power of Human Connection
04:45 PM - 05:45 PM
Salamander Washington DC - Gallery C

There is a growing body of evidence underscoring the importance of meaningful relationships and social connections to maintain physical and mental health. Social connectedness is associated with a 50 percent reduced risk of early death; conversely, loneliness and social isolation increase the risk of heart disease, dementia, and stroke. Social prescribing offers a new avenue to treat social connectedness as a critical health issue, enabling physicians to address social needs alongside other determinants of health such as housing and food. This panel will examine the relationship between health and social well-being, highlight promising models, and explore approaches to scale social prescribing. 

Moderator
Jennifer Wong
Director of Wallis Annenberg GenSpace, The Annenberg Foundation
Speakers
Anand Parekh
Chief Medical Advisor, Bipartisan Policy Center
Brian Robinson
Global Chief Strategy Officer, Havas Health & You
Mona Siddiqui
Senior Vice President, Home Clinical Operations, CenterWell, Humana
Trent Stamp
CEO, The Eisner Foundation
Women's Health Networking Reception (Invite only)
04:45 PM - 05:45 PM
Salamander Washington DC - Marina II

Women's health innovation and services are severely underfunded. As the political landscape is continually shifting, the need for investment is even greater. We have seen companies make pledges around climate and social justice, but how will women's healthcare fare in seeing dollars spent? During this reception, attendees will have an opportunity to put their voices together to discuss the issues and challenges, and brainstorm potential funding streams about how to best utilize capital to bridge existing gaps surrounding women's health services.

Navigating the Public Health Information Superhighway
05:10 PM - 06:00 PM
Salamander Washington DC - Grand Ballroom

COVID surges, Monkey Pox, Hep A on strawberriesoh my! Infodemiology is the study of the overabundance of information, both accurate and inaccurate, occurring during an epidemic. During this panel, we will take a deeper look into the flow of health communication and how we are all consuming information differently in the wake of COVID-19, impacting behavior and public health. How are we better at understanding public health risks and behaviors? Has social media's ability to quickly disseminate information affected the physical and mental health of users? Policy makers, health-care providers, and communities have the unique opportunity to leverage lessons from the pandemic, navigate big data sources, and capitalize on the collective heightened health consciousness to improve health. 

Moderator
Richard Tofel
Principal, Gallatin Advisory; Distinguished Visiting Fellow, Harvard T.H. Chan School of Public Health
Speakers
Lynn Goldman
Michael and Lori Milken Dean of Public Health, George Washington University
Jennifer Nuzzo
Professor of Epidemiology and Director, Pandemic Center at Brown University
David Rhew
Global Chief Medical Officer and Vice President, Microsoft
Dena Trujillo
CEO, Crisis Text Line
Health & Medical Research
Reception
05:45 PM - 07:00 PM
Salamander Washington DC - Grand Foyer

Badge Pick-up
07:30 AM - 05:00 PM
Salamander Washington DC - Grand Foyer
A Legacy of Innovation for Patients: A Conversation with US Representative Fred Upton
08:30 AM - 08:50 AM
Salamander Washington DC - Grand Ballroom
Guest
Fred Upton
US Representative, Michigan
Moderator
Michael Milken
Chairman, Milken Institute
Guest
Rahul Gupta
Director, Office of National Drug Control Policy, The White House
Moderator
Sabrina Spitaletta
Senior Director, Center for Public Health, Milken Institute
Health & Medical Research Policy, Politics, & Regulation
Meeting the Needs? The Inequity of Digital Health
09:00 AM - 10:00 AM
Salamander Washington DC - Gallery A

The digital health revolution promised to increase access to groundbreaking treatments as it leveled the playing field. However, though biopharma increasingly relies on digital health tools to accelerate innovation, patients are slow to adopt the new tools. Sensors, wearables, and digital therapeutics are frequently inaccessible and unfamiliar to the patients whom such tools are most likely to benefit. Their reluctance further exacerbates health inequities. What means can we use to eliminate infrastructural, institutional, and community-level barriers in order to increase access to, and awareness of, potentially life-enhancing digital health tools? What other barriers to equity need to be demolished, such as lack of access to broadband in under-represented communities? Panelists will discuss the use of digital health technologies and novel tools to address health equity across the R&D ecosystem. 

Moderator
Jon Fortt
Co-Anchor, TechCheck, CNBC
Speakers
Irene Dankwa-Mullan
Chief Health Equity Officer, Chief Health Officer, IBM Watson Health
John Doyle
Group Vice President, Exponent
Jennifer Goldsack
CEO, Digital Medicine Society
Lucia Savage
Chief Privacy and Regulatory Officer, Omada Health
Diversity, Equity, & Inclusion AI, Innovation, & Technology
Venture Philanthropy's Role in Improving Equitable Access to Health Care
09:00 AM - 10:00 AM
Salamander Washington DC - Gallery B

The last few years have seen the emergence of philanthropists seeking to improve equitable access to care, with aims ranging from greater availability of care providers in medically underserved areas, to lowering costs of prescription drugs. Although medical advances are made every year, it is increasingly apparent that not everybody has the same level of access to care. Specifically, the pandemic has further highlighted the need to focus on equitable access to care for all. Venture philanthropy can be invoked to lower barriers to development, expand access, and promote health equity in ways that government and industry often will not support. Examples of venture philanthropy improving access to health care can be seen in the launch of low-cost pharmacies, philanthropically supported HMOs, and venture philanthropic funds that de-risk drug development. In this session, we'll explore how venture philanthropy can enhance equitable access to health care.

Moderator
Melissa Stevens
Executive Vice President, MI Philanthropy, Milken Institute
Speakers
Allan Coukell
Senior Vice President of Public Policy, Civica RX
Alice Pomponio
Managing Director, BrightEdge and Vice President Innovation and Impact Investing, American Cancer Society
Aaron Seybert
Managing Director, Social Investment Practice, The Kresge Foundation
Geetha Tharmaratnam
Chief Impact Investment Officer, WHO Foundation
Philanthropy & Social Impact Diversity, Equity, & Inclusion
Reframing Aging: Designing for Longevity (Invite only)
09:00 AM - 10:00 AM
Salamander Washington DC - Phillips

By 2050, the number of older adults over 65 will more than double to an estimated 1.6 billion—representing one of the largest demographic shifts in human history. However, a retirement phase of life still anchors society's way of thinking, even though the vast majority of adults can expect to live decades past retirement age. We must move away from this legacy framing and focus on capacity, not age, and recognize how older adults contribute as workers, volunteers, advisers, community leaders, board members, active family members, and innovators. Learn more about the shifts individuals, societies, and governments need to go through to set us up for a future where one could be in school at 50 and still employed at 80.

Moderator
Katherine Linzer
Partner, McKinsey Health Institute
Speakers
Jisella Dolan
Chief Global Advocacy Officer, Home Instead Inc.
Marc Freedman
Founder and CEO, CoGenerate
Sanjay Khurana
Investor -in-Residence, Techstars Future of Longevity Accelerator
Abby Levy
Managing Partner and Founder, Primetime Partners
Feeding Change Business Council Private Breakfast (Invite only)
09:00 AM - 10:00 AM
Salamander Washington DC - Corcoran
Social Epidemiology: Public Health and Social Movements
09:20 AM - 10:00 AM
Salamander Washington DC - Gallery C

For the first time in decadesacross race, socioeconomic status, gender, and communityAmericans can expect shorter lifetimes. Socially impelled public health crises often drive adverse change. Gun violence, hunger, racism, suicide, and opioid abuse: All contribute to an increasingly unstable social and health environment. None of these issues are new or unknown, but progress towards long-term solutions is slowed by lack of social will and policymakers' inaction, among other barriers. Social movements are driven by advocates with well-known legacies. Panelists will explore what we can derive from cross-sector collaboration and lessons learned from the many social movements in public health. Can gun violence opponents learn from anti-tobacco campaigns? How have both been influenced by the AIDS crisis response? How have these movements grown and evolved over time? What common threads can we use for making a meaningful impact towards ending epidemic scourges in society? 

Moderator
Richard Ditizio
President, Milken Institute
Speakers
John Feinblatt
President, Everytown for Gun Safety
Robin Koval
CEO and President, Truth Initiative
Jesse Milan
President and CEO, AIDS United
Society & Culture Health & Medical Research Policy, Politics, & Regulation
An Update: Gun Violence as a Public Health Crisis
10:30 AM - 11:30 AM
Salamander Washington DC - Gallery C

Las Vegas Strip, Pulse Nightclub, Virginia Tech, Sandy Hook, Robb Elementary School, mass shootings and their aftermath have continued to dominate headlines in the midst of multiple public health crises. In Washington DC alone, 2022 is on track to become the most violent year in nearly two decades. Gun violence has become a chronic public health crisis in the United States, costing more than 110 lives each day, and more than $280 billion each year. The shared trauma among victims, families, and communities continues to spread as shootings become more frequent. Policymakers, companies, and clinicians are compelled to act in a way that instigates both policy change and harm reduction. Chief executives at over 220 American companies co-signed a letter urging members of the US Senate to take "bold, urgent action" to pass legislation to reduce gun violence in the US. Following on an important discussion at the 2019 Future of Health Summit, this panel will examine what meaningful progress has been made to confront gun violence in the US, and how communities, companies, and organizations can mitigate this uniquely American public health crisis. 

Moderator
Elisabeth Rosenthal
Editor-in-Chief, Kaiser Health News
Speakers
Georges C. Benjamin
Executive Director, American Public Health Association (APHA)
Kris Brown
President, Brady United
Babak Sarani
Director of Trauma and Acute Care Surgery and Co-Medical Director of Critical Care, George Washington University Hospital; Professor of Surgery and Emergency Medicine, GWU School of Medicine
Health & Medical Research Policy, Politics, & Regulation
Food Is Medicine: Opportunities to Maximize, Expand, and Scale
10:30 AM - 11:30 AM
Salamander Washington DC - Gallery A

In September, the White House published its National Strategy on Hunger, Nutrition, and Health, resetting the course of US food policy. The goal: "To make America truly a stronger, healthier nation." The strategy emphasizes integrating nutrition and health care through Food Is Medicine (FIM) innovations as a way to reduce the prevalence of chronic diseases through improved nutrition. Achieving these aims requires long-term effort, but many current policies only support temporary FIM interventions, such as produce prescriptions and medically tailored meals. In this session, we will discuss key priorities contained in the White House plan, as well as opportunities identified through the Milken Institute Financial Innovations Lab's collaboration with the Feeding Change: Food Is Medicine task force. Panelists from health insurance, government, and food retail sectors will share how they are experimenting to scale FIM programs and shift eating patterns to healthier options.

Moderator
Allison Aubrey
Correspondent, NPR News
Speakers
Sarah Fleisch Fink
Director for Policy Research and Development, Instacart
Rachel Krausman
Vice President, Social Determinants of Health, ProMedica
Catherine Oakar
Special Assistant to the President for Public Health and Disparities, The White House
Tambra Raye Stevenson
Founder and CEO, Women Advancing Nutrition Dietetics and Agriculture
Financial Markets Policy, Politics, & Regulation AI, Innovation, & Technology
The Future of Senior Housing: Building for Health, Engagement, and Accessibility
10:30 AM - 11:30 AM
Salamander Washington DC - Gallery B

According to a Milken Institute survey, affordable housing and connected health services are the two most critical policy interventions that local leaders must prioritize before 2030, as they prepare for aging populations. Although most older adults say they would prefer to age in their own homes, some will not be able to do so safely and affordably unless access to health and social services is connected to their housing by design. Responding to this need, payers have begun to lead the charge in directing investments towards integrated efforts that address social determinants of health on behalf of their investor-members, including affordable housing developments in markets across the county. During this session, experts in the field will discuss new ways to promote innovative models that integrate health and housing to enable older adults to thrive in future communities. 

Moderator
Kimberly Smathers
Managing Director, ATI Advisory
Speakers
Bob Kramer
Co-Founder, National Investment Center for Seniors Housing & Care; Founder, Nexus Insights
Tom Moriarty
Executive Vice President, Chief Policy and External Affairs Officer, and General Counsel, CVS Health
Katie Smith Sloan
President and CEO, LeadingAge
Business & Industry Policy, Politics, & Regulation
Prioritizing Accountability for Health Equity (Invite only)
10:30 AM - 11:30 AM
Salamander Washington DC - Phillips

Without accountability to prioritize health outcomes of minority populations, there cannot be true progress toward health equity. Many biomedical investigators recognize the paramount importance of health equity, yet progress has been slow. In this session panelists will identify those who are accountable for ensuring health equity goals are met. They will examine how progress is defined and measured, and where the funding for these accountability and equity initiatives can be found and sustained. Session participants will also discuss the internal and external metrics for justifying the funding of these programs. They will assess whatif anythingchanges in the absence of external drivers of social responsibility, such as lessened pressure from regional or federal governments. 

Moderator
Yasmeen Long
Director, FasterCures, Milken Institute
Speakers
Kevin Bugin
Deputy Director of Operations, Office of New Drugs, US Food and Drug Administration
Sally Okun
Executive Director, Clinical Trials Transformation Initiative
John Wigneswaran
Chief Medical Officer, Walmart
Diversity, Equity, & Inclusion
Lunch Plenary
12:00 PM - 01:30 PM
Salamander Washington DC - Grand Ballroom
Opening Remarks
Conrad Kiechel
Executive Director, Global Programming and Events, Milken Institute
Guest
Chiquita Brooks-LaSure
Administrator, Centers for Medicare & Medicaid Services
Moderator
Rick Berke
Co-Founder and Executive Editor, STAT
Part 2: Preventing the Next Pandemic: How Do We Avoid the Cycle of Panic and Neglect?
12:30 PM - 01:30 PM
Salamander Washington DC - Grand Ballroom

COVID-19 has shown the importance of strengthening global capabilities to detect and respond to outbreaks and public health emergencies. But in the midst of the COVID-19 pandemic, national commitments and public interest have begun to wane, as other pressing issues take precedence and consume mindshare. How can we continue to galvanize national governments to invest in pandemic prevention and preparedness? What steps are being taken to ensure these investments are being directed to address critical gaps and weaknesses and not duplicating efforts? How can we energize public support for these activities?

Moderator
Nino Kharaishvili
Global Health Director, Jacobs Solutions Inc.
Speakers
Priya Basu
Executive Head, The Pandemic Fund Secretariat, World Bank Group
Beth Cameron
Senior Advisor for Global Health, United States Agency for International Development (USAID)
Steve Davis
Former Executive Strategy Advisor, Bill & Melinda Gates Foundation; Former CEO, PATH
Terry Rauch
Acting Deputy Assistant Secretary of Defense, Health Affairs, Health Readiness Policy and Oversight, US Department of Defense
Carolyn Reynolds
Co-Founder, Pandemic Action Network
Financial Markets Health & Medical Research Policy, Politics, & Regulation
Technology Solutions for Food Is Medicine Prescriptions Lunch (Invite only)
12:00 PM - 01:30 PM
Salamander Washington DC - Marina I

With health-care-related costs continuing to rise, it is imperative to fund population health strategies that use food and nutrition as tools to treat and prevent costly diet-related diseases, as well as to feed food-insecure populations. This session will identify opportunities for private capital to enhance technology solutions to overcome the inefficiencies and fragmentation inhibiting both access to and scale of today's FoodRx prescriptions. Attendees will have an opportunity to brainstorm how new and existing technologies can be leveraged to facilitate greater data sharing, improve market efficiencies and demonstrate the value of these Food Is Medicine interventions, with a focus on how private markets can support the advancement of these solutions at scale.  

Moderators
Maressa Brennan
Director, Innovative Finance, Milken Institute
Holly Freishtat
Director, Feeding Change, Milken Institute
AI, Innovation, & Technology
At the Crossroads: Public Health and Climate Change
02:00 PM - 03:00 PM
Salamander Washington DC - Gallery B

Global advocacy to address the threat of climate change has become one of the leading social movements of our age. Rising temperatures, air pollution, growing scarcity of water, food distribution bottlenecks and famine, and the spread of infectious diseaseall of these climate-related factors contribute to the rapidly accelerating health concerns, particularly in children, underserved communities, and the populations of developing nations. How can we capitalize on public concern about climate change to address its root causes in a meaningful way? How can we ensure that public health concerns due to climate change and its effects don't become just another thing that humans are forced to endure? 

Moderator
William Brangham
Correspondent, PBS Newshour
Speakers
Stacy Bohlen
CEO, National Indian Health Board
Cristian-Silviu Bușoi
Member of the European Parliament; Chair of the Industry, Research and Energy Committee
Michael Nyenhuis
President and CEO, UNICEF USA
Seema Wadhwa
Executive Director of Environmental Stewardship, Kaiser Permanente
Sustainability & Environment Health & Medical Research
High-Tech and High-Touch: Solutions to Support Caregivers
02:00 PM - 03:00 PM
Salamander Washington DC - Gallery C

One need not look far to find one of the 50 million family caregivers in America. They are critical to meeting the needs of our aging population. But few of them have the support they need, and many of them experience physical, emotional, and financial strain. To lighten this burden, the public and private sectors must work together to create affordable long-term care options, broaden access to universal paid family leave, and develop technologies to assist with juggling life, work, and caregiving. This panel will explore promising, innovative solutions on the horizon. 

Moderator
Amy Goyer
National Family and Caregiving Expert, AARP; Author, "Juggling Life, Work and Caregiving"
Speakers
Joseph Coughlin
Founder and Director, Massachusetts Institute of Technology AgeLab
Jisella Dolan
Chief Global Advocacy Officer, Home Instead Inc.
Micky Tripathi
National Coordinator for Health Information Technology, US Department of Health and Human Services
Monique Woodard
Founder and Managing Director, Cake Ventures
Human Capital, Jobs, & Education AI, Innovation, & Technology
Is Long COVID the Next Public Health Emergency?
02:00 PM - 03:00 PM
Salamander Washington DC - Gallery A

The long-term debilitating effects of COVID-19 on people infected with the SARS-CoV-2 virus are a serious concern for clinicians, researchers and policymakers. Four months after diagnosis, almost half of COVID-19 survivors worldwide reported persistent symptoms including fatigue, memory problems, shortness of breath, sleep problems, and joint pain. Additionally, so-called "long COVID" may increase risk for heart attacks, diabetes, and dementia. Millions now confront continuing symptoms that interfere with the quality of life and impact productivity at work and home. The social, economic, and health security implications are profound. Where do we stand with research, treatment, and care for long COVID? What can we learn from related health conditions? Can we deploy the public health infrastructure as well as tools for prevention, diagnosis, and treatment put in place during the pandemic to grasp and address the long-term complications of COVID-19? 

Moderator
Jeannie Baumann
Senior Reporter, Bloomberg News
Speakers
Cynthia Adinig
Founder, BIPOC Equity Agency
Oved Amitay
Co-Founder, Long COVID Alliance; President and CEO, Solve M.E.
Gary Gibbons
Director, National Heart, Lung, and Blood Institute, National Institutes of Health; Co-Chair, RECOVER
Juan Wisnivesky
Chief, Division of General Internal Medicine, Mount Sinai Health System
Health & Medical Research
Food Is Medicine Task Force Annual Meeting (Invite only)
02:00 PM - 03:00 PM
Salamander Washington DC - Marina I
Partnering for Pandemic Prevention and Preparedness (Invite only)
02:00 PM - 03:30 PM
Salamander Washington DC - Phillips

The COVID-19 pandemic has spurred significant public investment in tools and resources to predict and prepare for future pandemics. Prioritizing and coordinating these investments will be essential to maximize impact and minimize redundancies. At the same time, the private sector can also bring to bear considerable tools, technology, and expertise to pandemic prevention and preparedness activities. How is the private sector being leveraged and integrated into public efforts? What are the mechanisms for broader partnerships? In this session, we will discuss current mechanisms for coordination and private sector engagement, as well as determine some immediate next steps we can take to facilitate new partnerships.

Moderator
Sung Hee Choe
Senior Director, FasterCures, Milken Institute
Speakers
Nelson Arboleda
Director, Office of the Americas, US Department of Health and Human Services
James Golden
Chief Data Officer, Pandemic Prevention Institute, Rockefeller Foundation, The Rockefeller Foundation
Ramiro Guerrero
Principal Health Specialist, Inter-American Development Bank
Matthew Lim
Head, Biosecurity and Health Security Protection, World Health Organization
Health & Medical Research Policy, Politics, & Regulation
Closing Plenary: The Future of Food and Health
03:30 PM - 04:30 PM
Salamander Washington DC - Grand Ballroom
Part 1: A Conversation with US Senator Cory Booker
03:30 PM - 04:00 PM
Salamander Washington DC - Grand Ballroom
Opening Remarks
Mr. Michael Klowden
CEO, Milken Institute
Guest
Cory Booker
US Senator, New Jersey
Moderator
Allison Aubrey
Correspondent, NPR News
Part 2: A Conversation with US Secretary of Agriculture Tom Vilsack
04:00 PM - 04:30 PM
Salamander Washington DC - Grand Ballroom
Guest
Tom Vilsack
Secretary, US Department of Agriculture
Moderator
Allison Aubrey
Correspondent, NPR News
The Philanthropic Path for Advancing Brain and Mental Health (Invite only)
03:30 PM - 04:30 PM
Salamander Washington DC - Marina I

The rapid progress of mental health and brain disorder-focused research has changed how we think and speak about mental health and the brain. A driver to this evolution is the influx of philanthropic capital to support brain-focused research, which is essential to millions of people living with mental health challenges and brain-based disorders. Although advances in brain-focused research and technology have begun to upend traditional clinical models, how do we continue to drive progress using philanthropy as a lever for change? This private session will feature philanthropic leaders and how their philanthropic mission relates to our understanding of mental health, the brain, and the path forward. 

Future of Health Summit Closing Reception
04:30 PM - 05:30 PM
Salamander Washington DC - Grand Foyer
Feeding Change Reception (Invite only)
04:30 PM - 05:30 PM
Salamander Washington DC - Marina II